Eli Lilly and Co. said that to address demand issues and increase access to its weight-loss drug tirzepatide, it will sell single-dose vials of the prescription medication in the US at prices significantly lower than what it charges for its auto-injector pens. Patients will be able to get the Zepbound vials only by paying out of pocket at the company’s LillyDirect website.
Full Story: HealthDay News (8/27), Medscape (8/27)